highly significantP < 0·001
6 ), the results revealed a highly significant reduction in DFS in 140 patients with high‐risk AMLo expression compared with 239 patients with low‐risk AMLo expression [85·5% vs. 98·3%; ( P < 0·001); Fig. 6 a].
6 ), the results revealed a highly significant reduction in DFS in 140 patients with high‐risk AMLo expression compared with 239 patients with low‐risk AMLo expression [85·5% vs. 98·3%; ( P < 0·001); Fig. 6 a].